Fairvalue-Calculator Fairvalue-Calculator
EN DE

Redsense Medical AB (REDS) Fair Value & Analysis

Healthcare · SE · Market cap 77.1M SEK

Pricekr 3.99
Fair Valuekr 6.25
Upside+56.6%
Quality95/100
Evidence: Low Range kr 4.69 – kr 7.82

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Redsense Medical AB (REDS) currently trades at kr 3.99, while our model-based Fair Value estimate is kr 6.25 — implying the stock looks roughly 56.6% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Redsense Medical AB (publ) provides an alarm in the event of blood leakage to monitor hemodialysis treatments in Europe, Canada, and Australia. It offers alarm units, such as Redsense, an alarm system for monitoring the blood access during hemodialysis; sensor patches to monitor venous needle or catheter access; and Redsense clamps to automatically stop the blood flow. The company was founded in 2000 and is headquartered in Halmstad, Sweden.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Redsense Medical AB (REDS) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 6.25 versus a price of kr 3.99 — about +57% (undervalued). Model-based estimate, not financial advice.
What is the fair value of REDS?
Our 21-model fair value for Redsense Medical AB is kr 6.25 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 3.99.
What is the quality score of REDS?
Redsense Medical AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.